Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Circulating CXCR5+CXCR3+PD-1lo Tfh-like cells in HIV-1 controllers with neutralizing antibody breadth
Enrique Martin-Gayo, Jacqueline Cronin, Taylor Hickman, Zhengyu Ouyang, Madelene Lindqvist, Kellie E. Kolb, Julian Schulze zur Wiesch, Rafael Cubas, Filippos Porichis, Alex K. Shalek, Jan van Lunzen, Elias K. Haddad, Bruce D. Walker, Daniel E. Kaufmann, Mathias Lichterfeld, Xu G. Yu
Enrique Martin-Gayo, Jacqueline Cronin, Taylor Hickman, Zhengyu Ouyang, Madelene Lindqvist, Kellie E. Kolb, Julian Schulze zur Wiesch, Rafael Cubas, Filippos Porichis, Alex K. Shalek, Jan van Lunzen, Elias K. Haddad, Bruce D. Walker, Daniel E. Kaufmann, Mathias Lichterfeld, Xu G. Yu
View: Text | PDF
Research Article AIDS/HIV

Circulating CXCR5+CXCR3+PD-1lo Tfh-like cells in HIV-1 controllers with neutralizing antibody breadth

  • Text
  • PDF
Abstract

HIV-1–specific broadly neutralizing antibodies (bnAbs) typically develop in individuals with continuous high-level viral replication and increased immune activation, conditions that cannot be reproduced during prophylactic immunization. Understanding mechanisms supporting bnAb development in the absence of high-level viremia may be important for designing bnAb-inducing immunogens. Here, we show that the breadth of neutralizing antibody responses in HIV-1 controllers was associated with a relative enrichment of circulating CXCR5+CXCR3+PD-1lo CD4+ T cells. These CXCR3+PD-1lo Tfh-like cells were preferentially induced in vitro by functionally superior dendritic cells from controller neutralizers, and able to secrete IL-21 and support B cells. In addition, these CXCR3+PD-1lo Tfh-like cells contained higher proportions of stem cell–like memory T cells, and upon antigenic stimulation differentiated into PD-1hi Tfh-like cells in a Notch-dependent manner. Together, these data suggest that CXCR5+CXCR3+PD-1lo cells represent a dendritic cell–primed precursor cell population for PD-1hi Tfh-like cells that may contribute to the generation of bnAbs in the absence of high-level viremia.

Authors

Enrique Martin-Gayo, Jacqueline Cronin, Taylor Hickman, Zhengyu Ouyang, Madelene Lindqvist, Kellie E. Kolb, Julian Schulze zur Wiesch, Rafael Cubas, Filippos Porichis, Alex K. Shalek, Jan van Lunzen, Elias K. Haddad, Bruce D. Walker, Daniel E. Kaufmann, Mathias Lichterfeld, Xu G. Yu

×

Figure 3

Transcriptional analysis of DCs from HIV-1 controller neutralizers.

Options: View larger image (or click on image) Download as PowerPoint
Transcriptional analysis of DCs from HIV-1 controller neutralizers.
(A) ...
(A) Heatmap representing 930 genes differentially expressed (FDR-adjusted P < 0.05) between peripheral blood mDCs from neutralizers (NT) and non-neutralizers (NN) (n = 4 patients in each group). (B) Left panel: Canonical pathways significantly (Signif.) upregulated (red) and downregulated (blue) (Fisher’s exact test, –log10 P values for each represented pathways are shown) in transcriptional signatures in mDCs from NT, as predicted by Ingenuity Pathway Analysis (IPA). Pathways in gray are significant but without known degree of functional activation/inhibition. Right panel: Circos plot representing genes shared between pathways differentially expressed in mDCs from NT. Inner circle reflects the log2 fold change in gene expression intensity between NT and NN. Pathways predicted to be activated in NT are highlighted in red in the outer circle; pathways in gray are significant but with unknown degree of functional activation. Inn/Adap Immun. Com., innate and adaptive immune communication; Cytosk., cytoskeleton; Ephrin R., ephrin receptor; S., signaling. (C) Significant putative upstream regulators with predicted activating (red) or inhibitory (blue) influence on transcriptional signatures in mDCs from NT, as determined by IPA. (D) Predicted network interactions of 5 putative upstream regulators of transcriptional signatures in mDCs from NT. Activating impulses are highlighted in orange; inhibitory signals are marked in blue. Target genes upregulated in mDCs from NT are labeled in red; downregulated genes are labeled in green. (E) Mean fluorescence intensity of surface levels of ICOS ligand (ICOS-L) and CD40 assessed by flow cytometry in gated mDCs from HIV-1 controller NN (n = 18) and NT (n = 24). Statistical significance was calculated using a 2-tailed Mann-Whitney U test (*P < 0.05). (F) Changes in proportions of PD-1lo (left) and PD-1hi (right) Tfh-like cells generated in the presence or absence of anti-CD40 blocking antibodies (n = 6 experiments). Differences were tested for significance using a 2-tailed Wilcoxon matched-pairs signed rank test (*P < 0.05).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts